INFO	ORM	IATI	ON DIS	SCLOS	URE CI	TATION	AT	ATTY. DOCKET NO. PC10434B SERIAL NO. 09/845,992									
(Use several sheets if newessary)								APPLICANT Howard Ralph Howard									
7 700 8								FILING DATE April 30, 2001					GROUP 1626				
			1	KK.O.J. To				PATENT	DOCU	MENTS	· · · · · · · · · · · · · · · · · · ·		,				
EXAMINE INITIAL	R	$\bot$		STEW!	THE DOC	CUMENT NUMBE	ER			DATE	NAME		CLASS	SUBCLASS	FILIN	IG DATE IF OPRIATE	
	<u>l</u> ı	JS	1	1	6	_ 1	5	2	9	11/23/15	R. R. Ringe	er					
				,													
	$\top$	$\top$													-		
	+	$\dashv$									ក្ន	<u>t</u>	7		-		
		-+		<del>  </del>					<u> </u>		<u>ر</u> آ	TECH CENTER 1800/2007	E C	<u> </u>	<del> </del>	<u></u>	
	+	$\dashv$		<b> </b>	<b>  </b>							<u>É</u>	0 3	n n	<u> </u>		
	_	$\dashv$		<u> </u>								豆	وم دع	5			
												B	183	Ö			
*						,			-			270	į				
			-									-	3				
	$\top$										<del>-</del>				$\vdash$		
						FO!	EFIG	N PATE	NT DO	CUMENTS	•				<u> </u>		
				<u> </u>										Т	,		
DOCUMENT NUMBER										DATE	COUNTRY		CLASS	SUBCLASS	TRANS	BLATION	
	$\top$							<u></u>	Γ.						YES	NO	
	E	<u>P</u>	0	5	1	6	2	3	4	5/25/92		$\longrightarrow$			—	-	
	E	Р	0	8	0	7	6	2	1	5/12/97	<del></del>				<u> </u>	_	
	s	υ	1	2	0	8	7	6	5	6/26/84							
	<u>s</u>	υ	2	1	3	9	2	7	7	2/14/97							
				OTHE	R DOCL	JMENTS	(Inclu	iding Aut	thor, Titl	e, Date, P	Pertinent Page	es, Et	 c.)	<u></u>		т	
			Database CSChem Chemical Sources International Inc. Potriound from STALD-tables Associated Acceptance in the Company of the Co														
			Database CSChem, Chemical Sources International, Inc. Retrieved from STN Database Accession No. 11250, XP002135477, 2-Aminomethyl-3-Chlorodipfenylether.														
				·													
			<del></del>														
EXAMIN	IEK								DATE C	ONSIDERED	)						
			<u></u>														
EXAMINER with next or	R: Initia ommur	al if refe nication	rence cons to applicar	sidered, whe nt.	ther or not cit	ation is in confo	rmance	with MPEP 60	9; Draw line	through citation i	if not in conformance a	and not c	onsidered.	Include copy of	f this for	m	

Conforms with FORM PTO-FB-A820

1626

Patent Application (Attorney Docket No.PC10434B

O RE JCS, 15 TO THE PERSON OF THE PERSON OF

I hereby certify that this correspondence is being deposited with the United States Postal Service as #Fst-class mail in an envelope address to: Commissioner of Patents, Washington, D.C. 20231 on this 2nd day of April 2003.

By

(Signature of person mailing)

A. David Joran
(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Harry Ralph Howard:

APPLICATION NO.: 09/845,992 : Examiner: Saeed, K. A.

FILING DATE: April 30, 2001 : Group Art Unit: 1626

TITLE: MONOAMINE REUPTAKE :

INHIBITORS FOR TREATMENT OF

**CNS DISORDERS** 

Commissioner for Patents Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97 (c) (1) AND CERTIFICATE UNDER 37 CFR §1.97 (e) (1)

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Since the references cited were cited in a communication from a foreign patent office in connection with a counterpart application not more than three months prior to this statement, no fee is believed to be due. However, if a fee is deemed to be due, the Commissioner is hereby authorized to charge all appropriate fees to cover this submission to Pfizer Deposit Account No. 16-1445.

A prompt and favorable response is earnestly solicited.

## CERTIFICATE UNDER 37 CFR § 1.97 (e) (1)

Applicants' undersigned attorney avers that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of this Information Disclosure Statement.

Date

Respectfully submitted,

A. David Joran

Attorney for Applicant(s)

Reg. No. 37,858

Pfizer Inc Patent Department, 5th Floor 150 East 42nd Street New York, NY 10017-5755 (212)733 -3381